Company intelligence / Profile preview

Seinda Pharmaceutical Corporation

Ownership: Private
Development stage: Phase 3

Overview

SY-201, their lead product for dry eye disease, has completed a Phase 2 double-masked, randomized, parallel, vehicle-controlled clinical trial in the United States. Previous trials in China showed patients experienced significant decreases in OSDI scores, increases in TBUT, and reductions in CFS scores.

Therapeutic areas: Ophthalmology
Modalities: Small peptides
Industry: Biotech

Drug pipeline

4 assets

SY-201

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Seinda Pharmaceutical Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seinda Pharmaceutical Corporation.

Explore the full profile